Tradestie Institutional Equity Comparison Engine

SYRE vs HALO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HALO Overall Edge

HALO Captures Institutional Edge (2โ€“2 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Halozyme Therapeutics, Inc. (HALO) driven by superior Valuation, Growth & Margin while SYRE counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus HALO at 9.5x Forward P/E and 56.7% operating margin (+39.2% YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against HALO sits in CONSOLIDATION (26th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HALO
SYRE N/M vs HALO 9.5x Fwd P/E
Growth & Margin Winner HALO
Op Margin 0.0% vs 56.7% ยท YoY +0.0% vs +39.2%
Momentum & Technical Winner SYRE
1Y +341.7% vs +36.9% ยท 52W Pos 88% vs 50%
Options & Structure Winner SYRE
UNCLASSIFIED (10th %ile IV) vs CONSOLIDATION (26th %ile IV)
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
HALO NASDAQ
Halozyme Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$97.43
-2.83% 1D
Market Cap $11.5B
1M Return -20.03%
1Y Return +36.86%
Forward P/E 9.5x
Unified AI Score
59.9 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 70.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SYRE +341.74% HALO +36.86% Spread: +304.88 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SYRE TTM Op. Margin: 0.0% HALO TTM Op. Margin: 56.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs HALO. Trailing 12-month operating profitability (SYRE 0.0% vs HALO 56.7%) and valuation multiples (SYRE N/M vs HALO 9.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SYRE (2) vs HALO (8)
Institutional Metric SYRE HALO Criterion Row Winner
Market Capitalization Scale $9.8B $11.5B Larger Scale HALO
Trailing P/E Ratio Valuation N/M 25.2x Lower Multiple HALO
Forward P/E Ratio Valuation N/M 9.5x Lower Multiple HALO
Revenue Growth (YoY) Growth +0.0% +39.2% Higher Growth HALO
Operating Margin (TTM) Profitability 0.0% 56.7% Higher Margin HALO
Net Profit Margin Profitability 0.0% 26.9% Higher Margin HALO
Return on Equity (ROE) Capital Efficiency -35.0% 216.4% Higher ROE HALO
52-Week Range Position Momentum 88% ($22โ€“$111) 50% ($61โ€“$134) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.75ฮฒ ยท 59% Vol 0.57ฮฒ ยท 59% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 36.1 / 100 (SELL) 59.9 / 100 (HOLD) Higher Composite HALO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SYRE vs HALO Buy Guide
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
HALO CONSOLIDATION
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live HALO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SYRE nor HALO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.